Search research articles
Contact Us
Filters
Showing results (111-120 of 157) with videos related to
Page
of 16
Sort By:
Journal of Geriatric Oncology
|
February 25, 2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
Andrew C Johns, Lai Wei, Madison Grogan, et al.
Investigational New Drugs
|
August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy
Adam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation
|
October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors
Sandip H Patel, Songzhu Zhao, Mingjia Li, et al.
BMC Cancer
|
May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
Daniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2022
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Dwight H Owen, Brooke Benner, Lai Wei, et al.
The Lancet. Oncology
|
August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.
Cancer Immunology, Immunotherapy : CII
|
February 16, 2023
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
Mingjia Li, Songzhu Zhao, Gabrielle Lopez, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 157) with videos related to
Sort By:
Page
of 16
Journal of Geriatric Oncology
|
February 25, 2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
Andrew C Johns, Lai Wei, Madison Grogan, et al.
Investigational New Drugs
|
August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy
Adam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation
|
October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors
Sandip H Patel, Songzhu Zhao, Mingjia Li, et al.
BMC Cancer
|
May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
Daniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2022
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Dwight H Owen, Brooke Benner, Lai Wei, et al.
The Lancet. Oncology
|
August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.
Cancer Immunology, Immunotherapy : CII
|
February 16, 2023
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
Mingjia Li, Songzhu Zhao, Gabrielle Lopez, et al.
Page
of 16